News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Key Points Interested in Boston Pizza Royalties Income Fund? Here are five stocks we like better. Sales reached a record: Royalty-pool franchise sales rose 1.9% year over year to C$256.5 million, while same-restaurant sales increased 2.3%, marking the seventh consecutive quarter of growth. Promotions, …
Versamet Royalties announced record operating and financial results for Q2 2026, including a 392% increase in revenue and a 256% increase in attributable gold equivalent ounces (GEOs) compared to Q2 2025. The company also completed the acquisition of a gold stream on the Eskay …
Versamet Royalties Corporation has reaffirmed its production guidance for the year 2026, targeting between 20,000 and 23,000 GEOs. This announcement comes as the company also reported an increase in its second-quarter profit and revenue. The company continues to advance its diverse portfolio of royalty …
Versamet Royalties (VMET) announced its Q2 2026 earnings on August 13, 2026, reporting an EPS of $0.04, missing analysts' consensus estimate of $0.06. The company's quarterly revenue was $23.73 million. VMET's earnings are projected to grow by 48.00% next year, from $0.25 to $0.37 …
Sharemaestro market context Price below Trend Line 36 weeks +11.1% · Next-week setup positive 58.5%Versamet Royalties Corporation announced a strong Q2 2026 with revenue surging to $23.7 million and net income jumping to $4.9 million, representing increases of 392% and 2,781% respectively, year-over-year. This growth was primarily driven by a record 5,255 gold equivalent ounces (GEOs) produced, a …
Altimmune Inc.'s President and CEO, Jerome Durso, recently purchased 15,000 shares of the company's stock, increasing his direct ownership to 62,500 shares. This transaction is part of a larger trend of insider buying at Altimmune, with 11 insider buys and no sells in the …
Versamet Royalties Corporation announced Q2 2026 revenue of $23.7 million, a 392% year-over-year increase, driven by a 256% rise in attributable gold equivalent ounces. The company reported a net income of $4.9 million and an adjusted EBITDA of $18.8 million, significantly up from the …
Versamet Royalties Corporation reported significantly higher revenues of $23.7 million in Q2 2026, up from $4.8 million a year prior, driven by an expanded portfolio and stronger commodity prices. The company also announced the acquisition of the Eskay Creek Gold Stream for $360 million, …
Sharemaestro market context Price below Trend Line 36 weeks +11.1% · Next-week setup positive 58.5%Altimmune, Inc.'s President and CEO, Jerome Benedict Durso, purchased 15,000 shares of the company's common stock at $2.95 per share on August 13, 2026. This transaction, conducted in the open market or a private transaction, increased his direct holdings to 62,500 shares. The Form …
Altimmune (ALT) reported a narrower-than-expected loss of 12 cents per share in Q2 2026, beating the Zacks Consensus Estimate of 15 cents. The company, which currently has no marketed drugs, focused on advancing its lead candidate, pemvidutide, with ongoing clinical studies for MASH, AUD, …
Altimmune, Inc. reported its second-quarter 2026 results, showing no revenue and a net loss of $(22.83M), with diluted loss per share at $(0.12). This represents an improvement in EPS compared to $(0.27) in Q2 2025. Key business highlights include the start of the PERFORMA …
AlTi Global's stock saw a slight increase after its Q2 2026 earnings report, with assets under management (AUM) rising to US$49.7 billion due to net inflows. Despite this growth in AUM, the company continues to report losses, with a basic loss per share of …
Dimensional Fund Advisors LP significantly increased its stake in Altimmune, Inc. by 268.7% during the first quarter, acquiring an additional 762,223 shares to own a total of 1.05 million shares valued at $3.22 million. Other institutional investors also adjusted their positions in Altimmune, which …
Altimmune Inc (ALT) reported Q2 '26 earnings with an EPS of -$0.12, beating the estimated -$0.14 by 11.44%. The company achieved significant clinical milestones, including initiating a Phase 3 MASH trial and positive Phase 2 results in AUD, while also advancing enrollment for its …
Earnings Call Insights: Altimmune (ALT) Q2 2026 MANAGEMENT VIEW * "2026 is proving to be a year of significant progress as Altimmune evolves into a late-stage company dedicated to serious liver diseases," said Chairman, CEO & President Jerome Durso, adding, "Last week we announced …
Sharemaestro market context Price below Trend Line 52 weeks -27.6% · Next-week setup negative 17.4%William Blair has reiterated its Hold rating on Altimmune (ALT.US). This indicates that the analyst firm recommends investors maintain their current position in the stock, without suggesting buying more or selling. The article does not provide specific reasons or financial data behind this rating.
Altimmune (NASDAQ:ALT) reported quarterly earnings, beating analyst expectations with a loss of $0.12 per share against an anticipated loss of $0.14. The company announced progress in its pemvidutide programs, including the start of the Phase III MASH trial and positive results from the Phase …
Altimmune, Inc. (ALT) announced its Q2 2026 financial results, reporting a narrower basic and diluted loss of $0.12 per share compared to the -$0.14 expected loss. The company posted $0 in revenue for the quarter, a 100% decrease from Q2 2025, and a net …
Altimmune reported a narrower-than-expected Q2 2026 loss of $0.12 per share, beating analyst estimates, as the biotech advanced late-stage trials for liver disease and alcohol use disorder. The company's shares rose 3.87% following the announcement. Altimmune highlighted a strong cash position of $519 million, …
Altimmune has initiated patient enrollment for its Phase III PERFORMA trial of pemvidutide for MASH and is advancing plans for later-stage development in AUD. The company reported positive topline results from its Phase II RECLAIM trial in AUD and completed enrollment for the Phase …
Altimmune reported a net loss of $22.8 million and held $519 million in cash for Q2 2026. The company highlighted significant progress in its pemvidutide programs, including the initiation of the PERFORMA Phase 3 MASH trial, positive topline results from the RECLAIM Phase 2 …
Search by ticker symbol or company name and select a result to open its chart.